Efficacy and safety of benralizumab in CRSwNP (OSTRO): randomised, placebo-controlled, phase 3 trial

Bachert C, Han JK, Wagenmann M, et al.

Lancet · 2024

Grade ARCTn=413
DOI ↗

Key Findings

  • ●Significant NPS and nasal blockage improvement
  • ●Near-complete tissue eosinophil depletion via ADCC
  • ●FDA-approved 2024 for CRSwNP
  • ●Benefit in high-eosinophil patients

Referenced in (1 disease)

Chronic Rhinosinusitis with Nasal Polyps
ID: doi-10-1016-s0140-6736-23-02873-0DOI: 10.1016/S0140-6736(23)02873-0